Allspring Global Investments
TCRT icon

Allspring Global Investments’s Alaunos Therapeutics TCRT Stock Holding History

Allspring Global Investments’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-649
Closed -$63K – 2924
2022
Q1 		$63K Sell
649
-64
-9% -$8.21K ﹤0.01% 2818
2021
Q4 		$116K Buy
+713
New +$157K ﹤0.01% 2750

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allspring Global Investments's TCRT Position: Q2 2022 in Review

Allspring Global Investments sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 649 shares — an estimated $63K sold.

Allspring Global Investments first reported a position in TCRT in Q4 2021 and held it in 2 quarters. The position peaked at $116K in Q4 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Allspring Global Investments reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Allspring Global Investments sold 649 Alaunos Therapeutics shares in Q2 2022, an estimated $63K.
  • Allspring Global Investments first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 2 quarters.
  • Allspring Global Investments's Alaunos Therapeutics position peaked at $116K in Q4 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Allspring Global Investments's 13F filing for Q2 2022, filed 25 Jul 2022.